Majedie Asset Management’s Ionis Pharmaceuticals IONS Stock Holding History

Majedie Asset Management’s Portfolio IONS Stock Details IONS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	$7.22M	Buy	195,492 +19,984	+11%	+$654K	0.59%	58
2021 Q4	$5.35M	Hold	175,508	–	–	0.41%	66
2021 Q3	$5.89M	Sell	175,508 -8,954	-5%	-$337K	0.45%	66
2021 Q2	$7.36M	Buy	184,462 +62,763	+52%	+$2.46M	0.48%	68
2021 Q1	$5.47M	Buy	121,699 +7,863	+7%	+$439K	0.4%	71
2020 Q4	$6.44M	Buy	113,836 +22,219	+24%	+$1.11M	0.49%	59
2020 Q3	$4.35M	Buy	91,617 +5,494	+6%	+$305K	0.32%	59
2020 Q2	$5.08M	Buy	86,123 +3,746	+5%	+$208K	0.39%	49
2020 Q1	$3.9M	Sell	82,377 -993	-1%	-$55.3K	0.36%	46
2019 Q4	$5.04M	Buy	83,370 +12,514	+18%	+$746K	0.37%	55
2019 Q3	$4.25M	Sell	70,856 -8,795	-11%	-$573K	0.36%	58
2019 Q2	$5.13M	Buy	79,651 +2,866	+4%	+$203K	0.39%	52
2019 Q1	$6.24M	Sell	76,785 -22,260	-22%	-$1.44M	0.44%	50
2018 Q4	$5.47M	Sell	99,045 -23,407	-19%	-$1.19M	0.41%	47
2018 Q3	$6.32M	Buy	122,452 +18,253	+18%	+$858K	0.48%	44
2018 Q2	$4.34M	Buy	104,199 +12,500	+14%	+$554K	0.34%	52
2018 Q1	$4.04M	Buy	91,699 +11,003	+14%	+$559K	0.37%	55
2017 Q4	$4.06M	Buy	80,696 +6,500	+9%	+$356K	0.34%	55
2017 Q3	$3.76M	Hold	74,196	–	–	0.31%	55
2017 Q2	$3.77M	Hold	74,196	–	–	0.36%	51
2017 Q1	$2.98M	Buy	74,196 +7,128	+11%	+$320K	0.32%	56
2016 Q4	$3.21M	Buy	67,068 +40,618	+154%	+$1.61M	0.43%	51
2016 Q3	$969K	Buy	26,450 +3,700	+16%	+$116K	0.16%	59
2016 Q2	$530K	Buy	22,750 +2,999	+15%	+$96.7K	0.09%	62
2016 Q1	$800K	Buy	19,751 +5,578	+39%	+$227K	0.12%	59
2015 Q4	$878K	Buy	14,173 +407	+3%	+$22K	0.12%	55
2015 Q3	$556K	Buy	13,766 +4,669	+51%	+$242K	0.09%	57
2015 Q2	$524K	Buy	9,097 +6,096	+203%	+$388K	0.09%	55
2015 Q1	$191K	Buy	3,001 +484	+19%	+$32.8K	0.04%	58
2014 Q4	$155K	Buy	+2,517	New	+$124K	0.03%	61

Other funds holding IONS

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

CCM

Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

TBC

Tweedy, Browne Co Stamford, Connecticut $1.26B AUM 33.88% 1-Year Est. Return

Majedie Asset Management's IONS Position: Q1 2022 in Review

Majedie Asset Management increased its Ionis Pharmaceuticals (IONS) stake by 11% in Q1 2022, buying an estimated $654K and bringing the position to 195,492 shares worth $7.22M. The position accounts for 0.59% of the portfolio, ranked #58.

Majedie Asset Management first reported a position in IONS in Q4 2014 and has held it in 30 quarters since. The position peaked at $7.36M in Q2 2021. 332 funds tracked by Wall St. Rank hold IONS as of Q1 2022.

Majedie Asset Management held 195,492 shares of Ionis Pharmaceuticals worth $7.22M as of Q1 2022.
Majedie Asset Management bought 19,984 Ionis Pharmaceuticals shares in Q1 2022, an estimated $654K.
Ionis Pharmaceuticals made up 0.59% of Majedie Asset Management's portfolio in Q1 2022, its #58 holding.
Majedie Asset Management first reported a position in Ionis Pharmaceuticals in Q4 2014 and has held it in 30 quarters since.
Majedie Asset Management's Ionis Pharmaceuticals position peaked at $7.36M in Q2 2021.
332 funds tracked by Wall St. Rank held Ionis Pharmaceuticals as of Q1 2022.

Based on Majedie Asset Management's 13F filing for Q1 2022, filed 16 May 2022.